RESEARCH MONOGRAPH · KDC-MN-237

Brexpiprazole

May 9, 2026 Kodiac biolabs Research Revised May 11, 2026 2 min read

Our opinion on this compound

71/100

Cleaner cousin of aripiprazole with less akathisia and a marginal-improvement story thats still useful

Brexpiprazole is what Otsuka did when they took aripiprazole's pharmacology and tuned the partial-agonist intrinsic activity downward. Brexpiprazole has lower intrinsic activity at D2 than aripiprazole (closer to 14 percent versus 30 percent), which means it behaves more antagonist-like in high-dopamine environments and produces less of the akathisia-tilted activation that aripiprazole sometimes generates. Same general partial-agonist scaffold, smoother clinical profile.

The 5-HT1A partial agonism is preserved, the 5-HT2A antagonism is preserved, the alpha-1 antagonism is actually higher than in aripiprazole, and the H1 antagonism is moderate. So brexpiprazole has a somewhat different side-effect spectrum than its parent compound. Less akathisia, more sedation, slightly more weight gain than aripiprazole but still well below olanzapine territory.

The clinical positioning has been mostly as an adjunctive treatment for major depression on top of an SSRI, where the pharmacology of partial D2 agonism plus 5-HT1A partial agonism plus 5-HT2A antagonism is a plausible augmentation strategy. The data on this is reasonable but the effect sizes have been modest. Schizophrenia indication is more recent and the data is solid but not striking versus existing options.

For research, brexpiprazole is a useful comparator alongside aripiprazole if youre dissecting how intrinsic-activity differences at D2 partial agonists produce different clinical and behavioral phenotypes. Same scaffold, tuned differently, side-by-side studies give you a clean read on what intrinsic activity actually does in vivo.

What we dont know is whether brexpiprazole genuinely offers a meaningful improvement over aripiprazole in clinical practice or whether its mostly a patent-extension play. The head-to-head data hasn't been particularly striking. Probably some patients tolerate it better, but as a class-advancement story its incremental.

Sourcing is acceptable. Reference material is available but per-gram costs are higher than for older atypicals because the compound is relatively new. HPLC validation is straightforward on clean material.

Solid, incremental, useful as a comparator. Not category-defining (sorry, banned word, lets say not field-changing), just better tuned.

Evidence: 75
Mechanism: 80
Reliability: 78
Safety: 78
Sourcing: 68
Value: 60
Signal: 60
Staying power: 65

Plain-language summary Intrigue 62 / 100

Brexpiprazole (Rexulti) is Otsuka's refined successor to aripiprazole, approved in 2015. The key tuning is lower intrinsic activity at the dopamine D2 receptor (about 14 percent rather than aripiprazole's 30 percent), which translates to less akathisia (motor restlessness), the side effect that drove many patients off aripiprazole. The receptor occupancy profile is otherwise broadly similar. Brexpiprazole has FDA approval for schizophrenia, as add-on to antidepressants for major depressive disorder, and notably became the first drug specifically approved for agitation associated with Alzheimer dementia in 2023. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

D2 partial agonist atypical antipsychotic

A second-generation D2 partial agonist refined from aripiprazole; lower D2 intrinsic activity producing reduced akathisia.

Abstract

Brexpiprazole (7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one; CAS 913611-97-9; molecular formula C25H27N3O2S; molecular weight 433.57) is a D2 partial agonist developed at Otsuka as a successor to aripiprazole and approved by the FDA in 2015 under the trade name Rexulti. The structural change from aripiprazole replaces the 2,3-dichlorophenyl with a benzothiophen-4-yl, modulating receptor binding kinetics. D2 affinity (Ki approximately 0.30 nM) is comparable to aripiprazole, but intrinsic activity is lower (approximately 14 percent versus 30 percent), producing reduced akathisia and less D2 receptor activation in low-dopaminergic-tone regions. 5-HT1A partial agonism (Ki approximately 0.12 nM) and 5-HT2A antagonism are retained. Plasma half-life is 91 hours; metabolism is via CYP3A4 and CYP2D6. Approved for schizophrenia, MDD adjunctive, and (2023) Alzheimer-associated agitation. Used as the reference second-generation D2 partial agonist with reduced intrinsic activity.

Mechanism of action

D2 partial agonist (lower intrinsic activity ~14 percent versus aripiprazole's ~30 percent). 5-HT1A partial agonist, 5-HT2A antagonist. Reduced akathisia.

Reported research dose ranges

Clinical 1 to 4 mg per oral administration daily. Rodent studies 0.1 to 3 mg/kg/day.

References

Maeda K, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther 2014.
Citrome L. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder. Int J Clin Pract 2015.
Frankel JS, Schwartz TL. Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Ther Adv Psychopharmacol 2017.

Read the full monograph

The full reference document is available below as a PDF embed and download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-237 Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Brexpiprazole

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs